To summarize and evaluate the literature on treatment approaches for oligometastatic and locally recurrent urothelial cancer.
There is no clear definition for oligometastatic urothelial cancers due to limited data.
Studies focusing on oligometastatic and locally recurrent urothelial cancer have been primarily retrospective. Treatment options include local therapy with surgery or radiation, and generalized systemic therapy such as chemotherapy or immunotherapy. Oligometastatic and locally recurrent urothelial cancers remain challenging to manage, and treatment requires an interdisciplinary approach. Systemic therapy is nearly always a component of current care in the form of chemotherapy, but the role of immunotherapy has not been explored. Consideration of surgical and radiation options may improve outcomes, and no studies have compared directly between the two localized treatment options. The development of new prognostic and predictive biomarkers may also enhance the treatment landscape in the future.
Current oncology reports. 2024 Apr 11 [Epub ahead of print]
Michael A Liu, Jennifer W Li, Karie Runcie
Division of Hematology and Oncology, Columbia University Irving Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA., Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA., Division of Hematology and Oncology, Columbia University Irving Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA. .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/38602581